secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001193125-24-001519
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Homology Medicines receives Nasdaq bid price deficiency notice; compliance deadline June 26, 2024
--------------------------------------------------------------------------------

- Received Nasdaq deficiency notice on Dec 29, 2023 for bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days, until June 26, 2024, to regain compliance by closing at $1.00+ for 10 consecutive business days.
- Plans to seek stockholder approval for reverse stock split in connection with proposed merger with Q32 Bio.
- If not compliant by June 26, may qualify for second 180-day period by transferring to Nasdaq Capital Market.
- Failure could lead to delisting, subject to appeal; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524001519/0001193125-24-001519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524001519/d648217d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-001519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer